Order Article Reprints

Curado F, Rösner S, Zielke S, Westphal G, Grittner U, Skrahina V, Alasel M, Malik AM, Beetz C, Böttcher T, et al. Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study. Diagnostics. 2023; 13(17):2812. https://doi.org/10.3390/diagnostics13172812

Curado, Filipa, Sabine Rösner, Susanne Zielke, Gina Westphal, Ulrike Grittner, Volha Skrahina, Mohammed Alasel, Ahmad Mehmood Malik, Christian Beetz, Tobias Böttcher, and et al. 2023. "Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study" Diagnostics 13, no. 17: 2812. https://doi.org/10.3390/diagnostics13172812

Curado, F., Rösner, S., Zielke, S., Westphal, G., Grittner, U., Skrahina, V., Alasel, M., Malik, A. M., Beetz, C., Böttcher, T., Barel, G., Sah, A. P., Dinur, T., Anjum, N., Ichraf, Q., Kriouile, Y., Hadipour, Z., Hadipour, F., Revel-Vilk, S., ... Rolfs, A., on behalf of the LYSO-PROOF Study Group. (2023). Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study. Diagnostics, 13(17), 2812. https://doi.org/10.3390/diagnostics13172812